Background. Type I antiarrhythmic drugs block the cardiac sodium channel in a use-dependent fashion. This use-dependent behavior causes increased drug binding and consequently increased sodium channel blockade at faster stimulation rates. Importantly, the kinetics of drug association and dissociation from the sodium channel differ for each type I antiarrhythmic drug.
sodium channel makes a transition from the resting to the active state. Both models assume minimal drug binding in the resting channel state (low drug affinity versus limited channel access). Membrane depolarization shifts the sodium channels into the active state and increases drug binding. Conversely, repolarization returns the channels to the resting state and promotes drug dissociation from the channel receptors. The rate of this dissociation process is largely responsible for the observed differences in the use dependence of type I antiarrhythmic drugs.5'6 Both models predict that in the presence of type I antiarrhythmic drugs, measures of sodium channel conductivity (VmI, 'Na) will progressively decrease as the rate of stimulation increases. Since myocardial conduction velocity is directly related to sodium channel conductivity, it should be possible to quantify in vivo use-dependent effects of type I antiarrhythmic drugs by measuring temporal changes in myo- 
Patient Population
The study group consisted of 35 patients receiving type I antiarrhythmic drugs for the treatment of sustained monomorphic VT. All patients were studied in the drug-free state to assure reproducible induction of sustained VT. This report details the outcome of 41 follow-up drug studies during which sustained monomorphic VT of an identical morphology remained inducible. Antiarrhythmic drugs studied were lidocaine (n=10), procainamide (n=16), and flecainide (n=15). The beat-to-beat cycle lengths of the tachycardia induced on drug therapy were compared with the drugfree state. In all cases except lidocaine, the drug study was performed on a separate day after achieving steadystate oral dosing of the study medication. Lidocaine testing was performed on the day of the control study after acute intravenous administration. For inclusion into the study group, arrhythmias induced during the control study had to show constancy of cycle length (<20 msec change in RR interval from onset to termination). In addition, an identical three-lead surface ECG morphology of the induced tachycardias during the control and follow-up drug study was required. Temporal changes in the beat-to-beat RR interval of the induced arrhythmias were assessed in the control and follow-up drug studies. The RR interval was measured at onset and 1, 2, 3, 4, 5, 7.5, 10, 15, 20, 25, 30, and 40 seconds after the onset of the tachycardia. For purposes of analysis, four primary end points were identified: 1) onset VT cycle length at the control study (C.n), 2) steady-state VT cycle length at the control study (CQ, t=30 seconds), 3) onset VT cycle length at the follow-up drug study (D.,), and 4) steady-state VT cycle length at the follow-up drug study (DSS t=40 seconds). Identical induction protocols were performed at the drug-free and follow-up studies. In selected patients, a SF arterial sheath was placed in the femoral artery to monitor arterial pressure.
Data Analysis
The VT cycle length was considered to reflect the conduction time through a relatively fixed reentrant circuit. It was assumed that the temporal increase in VT cycle length after tachycardia induction was secondary to a use-dependent binding of drug to the sodium channel. After induction of the arrhythmia, beat-to-beat changes in the RR interval were measured in all cases. For each induced tachycardia, the control VT cycle length at each time point was subtracted from the corresponding drug cycle length. A nonlinear regression analysis was then performed on the data to find the time constant of the change in tachycardia cycle length (Quasi-Newton least squares fit; SYSTAT version 5.0; Evanston, Ill.) to fit the data to an equation of the form Ch=CLss-(CL55-CLO.) e(-tlr) where CL,, CL,,, and CLO, represent the VT cycle length at any time t, steady state, and onset, respectively. The magnitude and rate constant of the usedependent prolongation of VT cycle length are represented by (CL,,-CL.,,) and a, respectively. The mean temporal data for each study drug were also subjected to regression analysis for clarity of comparative illustration. Group data are expressed as mean±SD. A paired t test was used to detect differences in control and drug VT cycle lengths at onset and steady state. One-way ANOVA was performed to detect differences in onset and steady-state VT cycle lengths among the study drugs (using a Scheffe test for multiple comparisons).
Results
All the patients in this study suffered from a previous myocardial infarction and recurrent scar-related VT. The mean age of the study population was 65±9 years, with a range of 42-78 years. There was no significant difference in age among the three drug groups. A male preponderance was observed in all three drug groups (see Table 1 ). The mean left ventricular ejection fraction of the study population was 41±11%. However, the ejection fraction of patients studied on flecainide was greater than that of either the IA or IB study groups (46±6 versus 39±11 and 37±13 respectively, p=0.04). This reflects our general practice of restricting the use of this drug to patients with an ejection fraction >39%. Electropharmacological testing was performed to identify an acceptable treatment regimen. A total of 41 drug studies were analyzed. Sixteen patients were studied on a type IA drug (procainamide), 10 were studied on a type IB drug (lidocaine), and 15 were studied on a type IC drug (flecainide). Seven patients were studied on two of the three test drugs.
The control VT cycle length at onset was similar in the three test drug groups and remained similar at steady state (see Table 1 ). No use-dependent change in the VT cycle length was observed in the drug-free state. After drug administration, the VT cycle length at onset was increased compared with control by both procainamide and flecainide but remained unchanged by lidocaine administration (see Figure 1 ). This drug-induced increase in onset VT cycle length will be referred to as "onset prolongation." After onset of the tachycardia, additional drug-induced prolongation of the cycle length occurred during a 40-second observation period. This secondary use-dependent prolongation of the VT cycle length contributed significantly to the steady-state VT cycle length during treatment with flecainide (mean onset VT cycle length, 330±48 msec; mean steady-state VT cycle length, 412±54 msec). The additional use-dependent increase in VT cycle length during treatment with lidocaine and procainamide was small. p=0.0001). The onset prolongation observed with both flecainide and procainamide was significantly greater than that seen with lidocaine (p<0.02). However, during the observation period, procainamide increased the mean VT cycle length by only an additional 19±27 msec compared with the onset value (p<0.01). Patients treated with flecainide demonstrated two distinct components of drug effect (see Figure 1) . The onset VT cycle length was prolonged by 81±49 msec compared with control (p=0.0001). However, the most distinctive marker of flecainide's effect was a slowly developing prolongation of the VT cycle length as the tachycardia persisted. This use-dependent prolongation of VT cycle length by flecainide accounted for over 50% (83±58 msec) of the observed increase in tachycardia cycle length. Use-dependent prolongation of VT cycle length by flecainide was significantly greater than that observed with either procainamide or lidocaine (p=0.0001).
The time constants of use-dependent VT cycle length prolongation by the three study drugs were significantly different (flecainide: 12 Nattel" confirmed this relation for lidocaine in canine cardiac Purkinje fibers and suggested that the use dependence of antiarrhythmic drug action should be amenable to in vivo quantification by the measurement of myocardial conduction delay.
The change in VT cycle length produced by the type I drugs in this report is consistent with a use-dependent decrease in myocardial conduction velocity. This conclusion assumes that the reentrant pathway remains constant. We attempted to control this variable by including only patients with stable monomorphic tachycardias that were identical in morphology during the control and follow-up drug study. Of course, minor changes in the local activation pathway may have occurred without producing detectable changes in the surface ECG pattern. The extent to which this may be responsible for the observed use-dependent changes in tachycardia cycle length remains uncertain. However, it should be noted that no significant change in the cycle length of the tachycardia occurred during the drug-free state. This along with the characteristic use-dependent response of the test drugs suggests that the observed cycle length prolongation was secondary to drug-induced slowing of myocardial conduction over a relatively fixed reentrant pathway.
Comparison With In Vitro Findings
The time course of in vitro use-dependent depression of Vmaa by type I antiarrhythmic drugs has been well characterized.5-7,l0,16 In our study, the estimated onset time constants of the tested antiarrhythmic drugs ranged from 0.52 seconds for lidocaine to 12.5 seconds for flecainide. Use-dependent conduction delay was most apparent during treatment with flecainide. Fifty percent of the increase in VT cycle length observed with flecainide was related to use-dependent cycle length prolongation (81±49 msec of onset prolongation versus 83±58 msec of use-dependent prolongation). The estimated time constant of flecainide's use-dependent cycle length prolongation is consistent with the reported time constants of use-dependent Vmax depression by flecainide (8.4-12.3 seconds) .5-7 Our result for procainamide is also similar to that reported for in vitro Vm,, depression (4.4-5.0 seconds).6'7 Many reports have described the in vitro effects of lidocaine on Vmax 1,6-8,11 The time constant of lidocaine's in vitro use-dependent reduction of Vmax is rapid (<0.2 seconds). In our report, no significant use-dependent prolongation of VT cycle length was observed during treatment with lidocaine. However, the onset VT cycle length was slightly increased compared with the control value. Since lidocaine's in vitro dissociation time constant is considerably less than the induction pace cycle length (200 versus 600 msec), we reasoned that no significant onset cycle length prolongation should occur with lidocaine. Onset Versus Use-Dependent VT Cycle Length Prolongation
The term "tonic block" has been used to describe the residual in vitro drug-induced reduction of Vm after a long resting period in a repolarized state. This rest period is sufficiently long (in relation to the drug's dissociation constant) to allow complete dissipation of use-dependent sodium channel blockade. A resting period of this duration cannot be achieved in a clinical protocol-especially in the case of a drug with slow use-dependent kinetics. Consequently, the druginduced change in the onset VT cycle length observed in our study should be considered to result from both tonic block and the use-dependent block incurred at the basic pace cycle length. A significant increase in the onset VT cycle length was observed with both flecainide and procainamide but not with lidocaine (see Table 1 and Figure 4 ). This difference in the three test drugs is consistent with their derived time constants of usedependent conduction delay. The time constants for both flecainide and procainamide significantly exceed the basic drive cycle length. Consequently, significant drug-induced prolongation of the onset VT cycle length is expected. The time constant for lidocaine is sufficiently rapid to allow nearly complete dissipation of block after each stimulated impulse. Consequently, an insignificant change in the onset VT cycle length should be expected with lidocaine. Limitations Interpretation of the cycle length changes observed in this study as a use-dependent sodium channel blocking effect requires that activation proceeds over a fixed reentrant pathway. Alternatively, it is arguable that the change in tachycardia cycle length was secondary to a changing conduction pathway. The findings favoring a use-dependent sodium channel blocking effect are 1) an insignificant change in the VT cycle length during the control study, 2) a uniform QRS morphology associated with the change in VT cycle length, and 3) distinct use-dependent time constants for each of the three test drugs. The last observation provides the strongest support for our conclusions, and the rank order of the time constants are consistent with known in vitro kinetics (flecainide > procainamide > lidocaine).
Voltage-dependent sodium channel inactivation (i.e., phase 3 block) could account for myocardial conduction delay during rapid ventricular pacing or tachycardia. This mechanism is unlikely to account for our observations. First, this effect would be more likely to occur during the control tachycardia inductions (because of their faster rates). Second, if present, phase 3 conduction delay should demonstrate "reverse" use dependence (i.e., progressive improvement in conduction) because of the expected rate-related shortening of the action potential duration.
Our protocol was limited to observation of the raterelated changes in myocardial conduction associated with an abrupt onset of tachycardia. Although this protocol is capable of illustrating the use-dependent effect of a drug with slow onset kinetics (flecainide), it is inadequate to fully characterize the in vivo effects of a drug with rapid onset kinetics (lidocaine). At the cycle lengths tested, lidocaine would be expected to demonstrate minimal use-dependent cycle length prolongation.
Clinical Implications
Recent reports have emphasized the potential deleterious or proarrhythmic risks of type I antiarrhythmic drug therapy.23 In particular, the rate-dependent conduction slowing associated with the type IC drugs (flecainide, encainide) has been implicated as a potential mechanism for drug proarrhythmia.20,24,25 In a theoretical model, Starmer and coworkers26 have demonstrated that drugs with slow use-dependent kinetics are capable of increasing the duration of a "vulnerable window" during which premature stimuli are capable of causing unidirectional block and reentrant activation. This proarrhythmic drug response was enhanced at faster stimulation rates. Further evidence for use-dependent type I proarrhythmia has been demonstrated in animal models,27-29 and Myerburg et a130 have suggested that type IC proarrhythmia may be reversed by treatment with propranolol. Our report clearly demonstrates that use dependence can contribute significantly to the observed sodium channel blocking effect of type I drugs -particularly type IC drugs such as flecainide. This effect may not always be detrimental. The usedependent increase in VT cycle length observed during flecainide treatment in this study was generally associated with improved hemodynamic tolerance of the tachycardia. However, the probability of benefit from this use-dependent effect must be balanced against the possibility of an increased spontaneous event rate.233' The relation of these proarrhythmic and antiarrhythmic drug effects to sodium channel blocking kinetics remains uncertain.
